Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Eli Lilly received FDA approval for its tirzepatide-based GLP-1 products, Mounjaro for diabetes and Zepbound for weight loss in May 2022 and November 2023, respectively
Shop Medications , Common GLP1-s include: Semaglutide (Ozempic, Wegovy, Rybelsus) from Novo Nordisk Tirzepatide (Mounjaro, Zepbound dual GLP-1/GIP) from Eli Lilly Liraglutide (Saxenda, Victoza) from Novo Nordisk Orforgliprofin (Foundayo) from Eli Lilly These medications help regulate blood sugar, reduce appetite, and support long-term weight loss, which can also reduce the risk of serious complications
The results of two drug trials were presented at the American Diabetes Associations annual meeting
The Q1 question is whether that growth engine is still accelerating, or whether volume strength is beginning to face more visible pricing and access headwinds
US$ 29.68
US$ 28.81
US$ 21.24
US$ 27.13
US$ 28.48
US$ 21.13
US$ 23.90
US$ 25.96
